Xerafy is set to highlight its innovative smart RAIN RFID labeling solutions at the upcoming AIPIA Innovation Stage during the CPHI South East Asia 2026 event, scheduled from July 8 to 10 in Bangkok, Thailand. The company aims to present cutting-edge RFID technologies that enhance pharmaceutical packaging and improve healthcare supply chain management.
Among the key offerings that Xerafy will exhibit are the XSKIN Gamma, designed for gamma-sterilized packaging, the MICRO Medical for identifying compact medical devices, and the Metal Skin Delta tailored for on-metal healthcare assets and metallized packaging. These RFID solutions are crafted to address the complexities of today’s pharmaceutical supply chains, allowing for item-level identification and real-time data acquisition throughout various stages, including manufacturing, sterilization, warehousing, and distribution.
The integration of smart RAIN RFID labels is transforming the pharmaceutical industry by offering improved product traceability, enhanced inventory accuracy, and ensuring compliance with regulatory standards. By linking physical products to digital records, these technologies provide a comprehensive view of product movement and handling, which is crucial in maintaining an efficient and transparent supply chain.
Xerafy emphasizes that its RFID solutions are particularly advantageous in challenging environments where traditional barcode systems may not perform optimally. This includes scenarios involving bulk handling, dense storage, and regulated healthcare applications. The company’s extensive portfolio features specialized RFID tags and labels catering to diverse sectors such as healthcare, manufacturing, logistics, aerospace, oil and gas, and data centers.
Through its participation at CPHI South East Asia 2026, Xerafy will demonstrate how the integration of connected packaging and advanced RFID technology can significantly streamline pharmaceutical and medical device supply chains, ultimately leading to better operational efficiency and improved patient outcomes.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.